Company intelligence / Profile preview

Pulmocide

London, England, United Kingdompulmocide.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Pulmocide’s lead asset, opelconazole, an inhaled antifungal azole, has shown promising results as both treatment and prophylaxis for serious Aspergillus-related lung diseases. It has been generally well tolerated in clinical studies and received multiple FDA designations to expedite development. The company’s pipeline also includes PC786, an antiviral targeting RSV.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small molecules (inhaled azole antifungals and antivirals)
Industry: Biotech

Drug pipeline

2 assets

opelconazole

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pulmocide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmocide.

Explore the full profile